Trials / Completed
CompletedNCT02963402
Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab
Analysis of Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 35 (actual)
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role. The study of these elements and its pathways could help identify the best responders to tocilizumab treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab | |
| DRUG | Adalimumab |
Timeline
- Start date
- 2016-11-09
- Primary completion
- 2018-10-01
- Completion
- 2018-10-01
- First posted
- 2016-11-15
- Last updated
- 2018-11-14
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02963402. Inclusion in this directory is not an endorsement.